⚖️ 280E Pressure, FDA Drift, And Nebraska’s Implementation Gap

Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.

Today’s edition moves from Washington tax posture to FDA tone, then into the states where implementation either stabilizes markets or quietly erodes credibility. Nebraska becomes the clearest case study of demand outrunning policy design, while New York and Minnesota show what rule correction looks like in real time. The throughline is simple: stability is earned through disciplined execution, not headlines.

Today’s edition is supported by Wispr Flow and The Deep View. To sponsor Policy, Decoded and reach the executives, investors, and policymakers who read this briefing, reply to this email and we will send details.

🎙️ New episode of The Hybrid drops today
📬 Sunday morning read-in analysis lands in your inbox
⚖️ Federal posture meets state reality

Meetings require preparation.

⚖️ CRS Puts 280E’s Constitutionality Back On The Table

The Congressional Research Service says Internal Revenue Code Section 280E keeps hammering state legal cannabis businesses as long as cannabis remains Schedule I. CRS also frames the Eighth Amendment Excessive Fines argument as unsettled enough to keep litigators interested, even after unfavorable outcomes in Tax Court. CRS gets mocked when lawmakers dislike the answer, and it keeps its credibility because it writes for Congress, not for advocates. For CFOs, this remains a planning problem before it becomes a legal theory, because tax posture drives hiring, expansion, and who survives a price war. Rescheduling talk may be the long runway, yet operators still need a short runway playbook that assumes 280E stays put through another budgeting cycle. (Cannabis Business Times)

🧪 FDA Validates Medical Use and Tightens Youth Frame

FDA Commissioner Marty Makary said marijuana shows medical benefit for some conditions while also flagging concern about side effects and youth exposure, including teen THC vaping. The politics are predictable: states will quote federal language when they tighten packaging, potency, and marketing, even in states that already have rules on the books. This is also where bureaucracy can slow roll even loud presidential directives, and the missed February 10th cannabinoid deadline reads like classic agency drift rather than urgency. Youth access has been a core regulatory frame since the Cole Memo era, and the glossy teen vaping problem has always looked more like nicotine’s playbook than cannabis’s. The premium now is adult-use discipline that is visible, enforceable, and boring. (Marijuana Moment)

🧃 David Trone of Total Wine And Breakthru’s Charles Merinoff Make The Case For Regulating Hemp Drinks

Total Wine founder David Trone and Breakthru Beverage co-chairman Charles Merinoff used WSWA Access Live to argue for regulation over prohibition for hemp THC beverages, with Trone pointing to mainstream buyer behavior and a low dose lane that can plausibly support age gating and product integrity rules. Trone is an important voice here because he can reach across state lines, and he has proximity to Congress that most category advocates do not. If he is willing to put his weight behind a regulated lane, that weight is considerable. The federal clock still matters, with warnings that Congress loses legislative oxygen after the August recess and the timeline still pointing toward a November cliff absent an extension. The decision point for the alcohol trade is whether it helps write durable standards now, or watches standards get written by lawmakers reacting to bad anecdotes. (Shanken News Daily)

🏫 New York Fixes Its 500 Foot Buffer Mess

Governor Kathy Hochul signed a bill that restores New York’s original entrance to entrance method for measuring the 500 foot buffer between dispensaries and schools or houses of worship. That change pulls 152 businesses back into compliance after OCM’s later guidance created a midstream zoning crisis with real money on the line. This closes one of the issues New York has had to confront, and fixing unforced errors still counts as progress. Lenders will notice the state took a self-inflicted risk off the table, and operators will notice the rules finally stopped moving under their feet. The longer work remains stability, throughput, and enforcement focus that stays steady for a full season, not a full news cycle. (Cannabis Business Times)

⚖️ Minnesota Judge Reopens Hemp Shipping

A Minnesota administrative law judge reversed OCM’s in person sales requirement for low potency hemp edibles and beverages, allowing direct shipment to customers again. The judge treated the shipping prohibition as an invalid rule that skipped the rulemaking process the law requires. Minnesota has served as a template for other jurisdictions on low dose hemp, and this decision highlights the hard part: writing guardrails that survive statutory scrutiny and scale in the real world. Direct to consumer access is exactly what divides the alcohol three-tier system, and it forces states to pick between channel protection and consumer convenience. The next move needs to be a workable compliance framework, because litigation will keep finding the seams where policy ambition outruns statutory authority. (Star Tribune)

🥤 Nebraska’s Hemp Drink Demand Outruns Policy

Nebraska’s hemp derived THC beverages have become a normal menu item in bars and retail, and state leadership is moving to squeeze the category through cease and desist pressure and an executive order pushing agencies to restrict intoxicating products. The theme keeps repeating across the country: when these products are offered in adult retail settings, consumers adopt them fast and treat them as normal. Demand is not the puzzle here. Policy design is. That includes clear definitions, testing, age gating, and the separation of disciplined low dose beverage models from synthetic and unregulated channels. Until Nebraska sorts that out, uncertainty freezes leases and capital, and it punishes responsible operators first because they carry fixed costs and reputational risk. (Flatwater Free Press)

🏛️ Nebraska’s Medical Program Is Legal On Paper And Still Closed In Practice

Crista Eggers of Nebraskans for Medical Marijuana told a Scottsbluff town hall that voters approved medical cannabis in 2024 and patients still cannot legally buy it. She named Governor Jim Pillen and Attorney General Mike Hilgers as the main sources of resistance, arguing lawmakers left the Medical Cannabis Commission without funding, staff, or basic infrastructure. Eggers also warned the current approach narrows the medical market through restrictive product form rules and leaves clinicians exposed because Nebraska has not passed good faith protections for recommendations, with LB 933 stalled. The human clock is the point, with her noting patients have died waiting while the state debates implementation mechanics. Nebraska’s credibility now depends on whether it builds a clinical program physicians will touch, or leaves families to improvise around the gaps. (Star-Herald)

🛑 Missouri Senate Hits Pause On A Fast Hemp Ban

A proposal to immediately ban intoxicating hemp products stalled in the Missouri Senate after Sen. Karla May led roughly two hours of resistance. States are stuck sifting through congressional tea leaves, consumer demand, and border competition, and it is an unenviable position. The pause reflects deliberate policymaking, and that matters, because overnight cutoffs strand inventory and create the exact whiplash conditions that reward the weakest actors. Missouri has lived the proxy war dynamic before, where hemp rules become a stand-in fight between industries and the state ends up with enforcement confusion. If lawmakers want the gray market to shrink, they need a transition path with clear definitions and testing rules that can be enforced on a Tuesday afternoon. (Missouri Independent)

📝 Alabama Opens Public Comment On Ownership and Transport Rules

The Alabama Medical Cannabis Commission voted to send proposed rule changes to public comment for at least 35 days, focusing on ownership change procedures and tighter security for transporting lab samples. This is the commission trying to convert early operational friction into clearer process, and that work matters because ownership changes and chain of custody issues are where credibility breaks first. The near term question is pacing: rule refinement is necessary, and patients still measure the program by access, not by agendas and meeting calendars. The commission also drew a clean line that the updates will not affect certified recommending physicians or already licensed companies, which helps reduce market panic while the rules get tightened. If Alabama wants public trust, these revisions need to read as disciplined governance that accelerates safe rollout, not another layer that slows it down. (WVTM 13)

🎟️ Rhode Island’s Lottery Front Door Is Becoming A Litigation Trap

Jason Calderon of Bonsai Buds secured North Kingstown planning approval for a Post Road dispensary site, and an abutter appeal in R.I. Superior Court by Janet Kurucz now puts his lottery eligibility at risk with the March 1 zoning documentation deadline approaching. The Cannabis Control Commission’s rule requiring final local zoning approval is clean on paper and messy in practice, because the easiest way to knock out a smaller applicant is to tie them up in municipal process or court calendars they cannot control. Well-financed operators can spread bets across multiple sites and towns, and a single appeal can wipe out a mom-and-pop plan that did everything right. Pawtucket’s late moving zoning timeline shows the same structural problem, with applicants expected to meet a statewide deadline while cities are still deciding what the rules are. The Commission’s next credibility moment is whether it treats these timing snares as a predictable barrier to entry and adjusts, or lets procedure decide who gets access to a market that was sold as opportunity. (Providence Business News)

🏚️ Planet 13 Exits California After Megastore Losses

Planet 13 is exiting California retail after selling and shutting down its Santa Ana superstore, with Catalyst Cannabis taking over the location. Planet 13 executives described the site as a persistent cash drain and said closing the Santa Ana store and a California production facility should save roughly $300,000 to $350,000 per month. Megastores are a hard model to replicate when your core revenue engine is essentially one product category with brutal price compression. Novelty can fill a room once, and it struggles to fill a P&L every month. California keeps rewarding retailers who treat cannabis like a disciplined, repeatable consumer business, not a destination attraction with fixed costs that assume the good years never end. (SFGATE)

🗳️ West Virginia Democrats Try To Put Legalization On The Ballot

Del. Shawn Fluharty says West Virginia is watching cannabis dollars flow across the border as Ohio ramps adult use and Pennsylvania presses legalization through the budget lane. His move is procedural, aiming for a constitutional amendment and a public referendum process because West Virginia lacks citizen initiated ballot mechanics. Domino pressure does not make implementation easier, and West Virginia is already sitting on a pile of medical marijuana money it has not dispersed. The state also carries deep scars from the opioid era, and that history should push lawmakers toward careful public health design without blurring cannabis into opioid panic language. If West Virginia wants credibility, it needs a rollout plan that treats revenue claims as a budget exercise, not a campaign slogan. (WV News)

🚀 Gotham Builds A Real Brand Pipeline For Black Founders

Gotham launched the Gotham Growth Project, an accelerator aimed at supporting Black owned cannabis consumer brands in New York City. Accelerators are worthwhile when they incubate execution, and they also raise real questions about ownership and control that have to be handled cleanly in a heavily regulated market. The structure here looks aimed at tangible outcomes: mentorship across positioning, regulatory alignment, retail readiness, and capital preparedness, followed by a pitch showcase in October. New York’s equity debate has spent years parked at licensing, and brand scale is where many social equity stories stall out quietly. Programs like this matter when they translate into shelf space, reorder velocity, and durable distribution, not just applause. (Black Enterprise)

🏥 Washington House Backs Hospital Access For Terminally Ill Cannabis Patients

The Washington State House passed a bill that would allow terminally ill patients to use medical cannabis in hospitals, addressing a long running gap between state legality and institutional policy. Expansion to hospice and end of life care is compassionate, and it also asks facilities dependent on Medicare and Medicaid reimbursement to get comfortable with a Schedule I substance. That federal tension has always been the holdup for institutional caregivers in other jurisdictions. The case for access is straightforward: cannabis can support pain, appetite, and comfort in ways many patients prefer to prescription heavy regimens. The implementation details decide whether this survives, including storage protocols, physician oversight, staff training, and clear lines that keep hospitals out of improvisation. (Cannabis Culture)

📊 Germany’s Early Legalization Data Looks Quiet Where Critics Predicted Chaos

Researchers at University Medical Center Hamburg-Eppendorf report no significant short term change in adult use or driving under the influence in the months after Germany’s CanG reforms and the new 3.5 ng THC blood serum limit. Use rose in Germany, yet a similar rise showed up in Austria, which weakens the claim that the law alone drove behavior. The sharpest early change landed in the justice system, with recorded cannabis offenses down and a large volume of low level cases falling out of criminal processing. The EU also carries interesting potential for medical advances, particularly around clinical trials and cross-border learning as other countries watch Germany’s rollout. The next decision point is implementation design, because cultivation associations still appear too small to displace illicit supply, and outcomes will hinge on access rules, enforcement prioritization, and public health investment. (Cannabis Health News)